177lu-jh04
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 21, 2024 (NCT06636617)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibroblast activation protein alphaBINDING AGENT
FAP binding agent
Chemistry & pharmacology
- Payload
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06636617 | Early Phase 1 (Phase 1) | Aug 21, 2024 | Fujian Medical University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1